EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics

Justin W Magrath, Madelyn Espinosa-Cotton, Dane A Flinchum, Shruthi Sanjitha Sampath, Nai Kong Cheung, Sean B Lee

Frontiers in Cell and Developmental Biology · 30.07.2024 · 12

DOI: 10.3389/fcell.2024.1442488 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 30.07.2024. Verfasst von Justin W Magrath und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA, United States. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Desmoplastic Small Round Cell Tumor (DSRCT) is a highly aggressive pediatric cancer caused by a reciprocal translocation between chromosomes 11 and 22, leading to the formation of the EWSR1::WT1 oncoprotein. DSRCT presents most commonly in the abdominal and pelvic peritoneum and remains refractory to current treatment regimens which include chemotherapy, radiotherapy, and surgery. As a rare cancer, sample and model availability have been a limiting factor to DSRCT research. However, the establishment of rare tumor banks and novel cell lines have recently propelled critical advances in the understanding of DSRCT biology and the identification of potentially promising targeted therapeutics. Here we review model and dataset availability, current understanding of the EWSR1::WT1 oncogenic mechanism, and promising preclinical therapeutics, some of which are now advancing to clinical trials. We discuss efforts to inhibit critical dependencies including NTRK3, EGFR, and CDK4/6 as well as novel immunotherapy strategies targeting surface markers highly expressed in DSRCT such as B7-H3 or neopeptides either derived from or driven by the fusion oncoprotein. Finally, we discuss the prospect of combination therapies and strategies for prioritizing clinical translation.

Schlagwörter

Stichwörter der Autor:innen

DSRCTfusion oncogenepediatric cancersarcomatargeted therapy

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA, United States.
  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Förderung

  • NCI NIH HHS

Zitieren

APA

Magrath, J. W., Espinosa-Cotton, M., Flinchum, D. A., Sampath, S. S., Cheung, N. K., & Lee, S. B. (2024). Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics. Frontiers in Cell and Developmental Biology, 12. https://doi.org/10.3389/fcell.2024.1442488

Vancouver

Magrath JW, Espinosa-Cotton M, Flinchum DA, Sampath SS, Cheung NK, Lee SB. Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics. Frontiers in Cell and Developmental Biology. 2024;12. doi:10.3389/fcell.2024.1442488

BibTeX
@article{Magrath2024,
  author = {Magrath, Justin W and Espinosa-Cotton, Madelyn and Flinchum, Dane A and Sampath, Shruthi Sanjitha and Cheung, Nai Kong and Lee, Sean B},
  title = {Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2024},
  volume = {12},
  doi = {10.3389/fcell.2024.1442488}
}
Kostenlos starten →